consolidated financial results for quarter ended March 31st, 2023.
▪ One–India: Robust growth across branded prescription, trade generics and consumer health over last year; 16% YoY growth adjusted for covid.
▪ US business: Reported highest ever revenue of $204Mn and 27% YoY growth driven by
expansion in market share of key launches.
▪ SAGA: Overall SAGA region faced headwinds earlier this year due to supply
challenges, however, business has picked up in private market with QoQ growth of 5%
in ZAR terms.
▪ R&D investments stands at INR 371 crores or 6.5 % of sales; Higher by 15% YoY driven by
continued progress of clinical trials on key pipeline assets.
“I am pleased to share that we continue to make significant progress across our focused markets.
In FY23, we recorded highest ever revenue with EBITDA crossing INR 5,000 Cr for the first time. Our
One–India business continued the double–digit trajectory growing at 13% ex–Covid during the year
led by branded prescription and sustained growth across our acute and chronic therapies. Our
continued focus on differentiated portfolio has strengthened our US business which posted highest
ever quarterly revenue at $ 204 Mn and $ 733 Mn for FY23. Adjusting for covid, our core operating
profitability continues to be strong at ~23% expanding by 100 bps over last year. We are excited
for the upcoming year, where we look forward to deepening our leadership in branded markets
and expanding our differentiated pipeline in the US.”
Umang Vohra MD and Global CEO, Cipla Ltd
